The American College of Obstetricians and Gynecologists (ACOG) has released updated menopause treatment guidelines for the first time since 2014, introducing a much broader spectrum of hormonal and non-hormonal options to manage symptoms such as hot flashes, insomnia, and mood swings.
Key Takeaways
- Expanded Options: The new ACOG guidance emphasizes an individualized approach, incorporating hormone replacement therapy (HRT), new non-hormonal drugs, and psychological interventions.
- HRT Safety Re-evaluated: Recent research suggests the safety of hormone therapy is “well-established” for women under 60 or within 10 years of their final menstrual period.
- Non-Hormonal Breakthroughs: New FDA-approved medications like fezolinetant (Veozah) and elinzanetant (Lynkuet) offer targeted relief for vasomotor symptoms.
- CBT for Sleep: Cognitive Behavioral Therapy (CBT) is identified as a promising, feasible treatment for menopause-related insomnia and night sweats, though benefits may diminish after three months.
- Individualized Care: Clinicians are encouraged to move away from “one-size-fits-all” tiers and instead tailor treatments to specific patient preferences and medical histories.
- Undiagnosed abnormal genital bleeding
- Current or past histories of certain gynecologic cancers
- A history of blood clots or stroke
- A history of heart attack
- Liver disease
- Known or suspected pregnancy
- Fezolinetant (Brand name: Veozah): Approved in 2023, this medication targets the biological mechanisms of temperature regulation.
- Elinzanetant (Brand name: Lynkuet): Approved in 2025, this drug provides an additional option for managing menopausal symptoms.
- Insomnia severity: Reducing the frequency and intensity of disturbed sleep.
- Sleep self-efficacy: Increasing a patient’s confidence in their ability to fall and stay asleep.
- Depressive symptoms: Addressing the emotional toll of chronic sleep loss.
- Hot flash interference: Reducing how much night sweats disrupt the sleep cycle.
- Diet and Exercise: Regular physical activity and a healthy diet are foundational to managing overall health during menopause.
- Mindfulness-Based Interventions: Techniques to manage stress and emotional volatility.
- Clinical Hypnosis and Acupuncture: Alternative methods to mitigate specific physical symptoms.
- If you are experiencing severe vasomotor symptoms: Ask your provider about the safety of HRT relative to your age and medical history. If hormones are not an option, inquire about newer non-hormonal medications like Veozah.
- If sleep is your primary concern: Discuss Cognitive Behavioral Therapy (CBT) with your clinician. It may be a highly effective way to regain control over your sleep hygiene without relying solely on medication.
- If you are concerned about long-term risks: Request a detailed discussion about your personal risk profile, including history of blood clots, cancer, or cardiovascular issues, to determine the safest path forward.
- Pharmacy Supply Chain Stability: Addressing the shortages of transdermal estrogen will be critical to ensuring patients can access their prescribed therapies.
- Expanded Clinical Research: Further studies will be needed to determine how to sustain the benefits of CBT beyond the initial three-month window.
- Regulatory Oversight: The FDA’s previous decision to scrap the “black-box warning” on certain estrogen therapies suggests a regulatory environment that is becoming more receptive to the benefits of HRT when used appropriately.
- Integration of Care: Expect to see more multidisciplinary approaches where OB/GYNs work more closely with psychologists and nutritionists to provide the “individualized approach” ACOG is now recommending.
- www.femtechworld.co.uk
- www.npr.org
What Happened
On Thursday, the American College of Obstetricians and Gynecologists (ACOG) officially published its first major update to menopause management protocols in over a decade. The guidance, developed by a committee of experts, aims to address the evolving landscape of menopausal care, which has seen significant scientific advancements since the previous 2014 standards were set.
According to Catherine Cansino, MD, MPH, an obstetrician/gynecologist and chair of ACOG’s Committee on Clinical Practice Guidelines, the core shift in these new menopause treatment guidelines is the sheer breadth of available tools. “What’s changing is the breadth of options that we now have … And the benefit of that is that we are better equipped to be able to take an individualized approach for patients,” Cansino said.
The updated document provides clinicians with a roadmap for treating the diverse symptoms that characterize the menopausal transition, including hot flashes, night sweats, sleep disturbances, and emotional fluctuations. It also provides much-needed clarity on the safety and efficacy of hormone replacement therapy (HRT), a topic that has been subject to intense scrutiny and public debate for the last two decades.
Why It Matters
Menopause is not a rare occurrence; it is a universal biological milestone for millions of women. Approximately 2 million women begin the transition into menopause every year. With the average age of menopause occurring at 49.9 years, the symptoms—which can begin years before the final menstrual period—often strike during a woman’s most productive professional and personal years.
The significance of these updated guidelines lies in their ability to mitigate the long-term health risks associated with poorly managed menopausal symptoms. For instance, the Menopause Society has noted that symptoms like insomnia and hot flashes are linked to serious health complications, including cardiovascular disease, depression, and increased healthcare costs.
Furthermore, the prevalence of these symptoms is staggering. Data from The Menopause Society indicates that hot flashes affect between 60% and 80% of women during the transition, while insomnia impacts an estimated 20% to 60% of perimenopausal and postmenopausal women in the United States. By providing clearer, more evidence-based pathways for treatment, ACOG aims to improve the quality of life for this massive demographic.
The Evolution of Hormone Replacement Therapy (HRT)
For much of the early 21st century, the medical community’s approach to menopause was heavily influenced by the 2002 Women’s Health Initiative (WHI) study. That research suggested a potential link between hormone replacement therapy and increased risks of heart disease, breast cancer, stroke, and pulmonary embolism. This led to a period of widespread hesitation among both physicians and patients regarding hormonal interventions.
However, the new menopause treatment guidelines reflect a more nuanced understanding of that data. Researchers revisiting the WHI findings noted significant limitations, most notably that the majority of the study participants were 60 years of age or older. This made it difficult for clinicians to apply the findings to younger women experiencing perimenopause or early menopause.
Robert Kauffman, MD, MSCP, a co-author of the new guidelines, provided specific parameters for when hormone therapy remains the gold standard. “Hormone therapy is probably the best option for symptomatic, newly menopausal women within 10 years of the final menstrual period or before the age of 60,” Kauffman stated during a press briefing on Thursday.
Understanding HRT Protocols
The guidelines provide specific recommendations based on a patient’s anatomy and medical history:
| Patient Profile | Recommended Hormone Protocol | Reasoning |
|---|---|---|
| Women with a uterus | Systemic HRT (Estrogen + Progestogen) | Progestogen is necessary to mitigate the risk of endometrial cancer caused by estrogen-induced uterine lining growth. |
| Women without a uterus | Estrogen alone | Without a uterus, the risk of endometrial cancer is not a factor in this specific context. |
| Patients seeking alternatives to standard HRT | Duavee (Estrogen + Bazedoxifene) | Bazedoxifene is a selective estrogen receptor modulator (SERM) that protects bone density while blocking estrogen’s effect on breast tissue. |
Contraindications and Risks
Despite the improved safety profile for younger women, ACOG emphasizes that hormone therapy is not appropriate for everyone. Physicians must screen for specific contraindications before prescribing HRT. According to the guidelines, hormone therapy should be avoided in patients with:
New Non-Hormonal Frontiers
One of the most significant developments highlighted in the new menopause treatment guidelines is the emergence of targeted, non-hormonal pharmacological options. For women who cannot tolerate hormones or who have contraindications, these drugs offer a specialized way to manage vasomotor symptoms (hot flashes and night sweats).
Two recent FDA approvals are central to this new category:
These medications do not work like traditional hormones. Instead, they function by blocking specific chemical messengers in the brain’s hypothalamus—the region responsible for regulating body temperature and managing sleep/wake cycles. Dr. Cansino noted that the excitement surrounding these drugs stems from the fact that they were developed based on a sophisticated understanding of the physiology of thermoregulation and sleep.
The Psychological Component: CBT and Lifestyle
While pharmacological interventions often take center stage, the new ACOG guidance places significant weight on non-pharmacological approaches. This includes lifestyle modifications and psychological therapies, specifically Cognitive Behavioral Therapy (CBT).
The Promise of CBT
A recent pilot study has identified CBT as a promising intervention for the dual challenges of insomnia and nocturnal hot flashes (night sweats). CBT is a structured, short-term “talking treatment” designed to help patients modify the thoughts and behaviors that can exacerbate sleep disturbances.
Dr. Monica Christmas, Associate Medical Director for The Menopause Society, highlighted the importance of these psychological tools. “Nocturnal hot flushes (night sweats) and sleep disruption can have a significant effect on the quality of life with many women claiming extreme impairment due to symptoms that often start in early perimenopause and last 10 or more years,” Christmas said.
Research indicates that CBT can improve several key metrics, including:
However, the research also includes a notable caveat: the therapeutic benefits of CBT appeared to diminish after a three-month period in the study. This suggests that while CBT is a highly feasible and effective tool, it may serve better as a short-term intervention or as an adjunct to other long-term management strategies.
Lifestyle and Holistic Interventions
For patients who prefer to avoid medication entirely, ACOG points to several lifestyle-based interventions. While the evidence for these is considered “weaker” than the evidence for HRT, they remain vital components of a holistic care plan. These include:
Dr. Cansino noted that in her own practice, many patients opt for non-pharmacologic routes. “A healthy diet and regular physical exercise is going to go a long way. So let’s start with that,” she said, emphasizing that these should be the starting point for many conversations.
What It Means for You
If you are currently navigating the symptoms of menopause or perimenopause, the update to these menopause treatment guidelines means you have more agency and more options than in previous decades.
Ultimately, the goal is to avoid “tunnel vision.” As Dr. Cansino warned, patients should avoid focusing exclusively on one single option and instead work with a trusted clinician to weigh the pros and cons of various treatments.
Counterpoints and Open Questions
Despite the progress, several challenges remain in the field of menopausal care. One immediate concern is the availability of treatment. In recent months, pharmacies have reported difficulty keeping estrogen products, such as transdermal patches, in stock. Dr. Cansino noted that these shortages highlight a critical imbalance: while there is intense public attention on hormone therapy, there may not be enough simultaneous focus on or availability of alternative treatments.
Furthermore, the “one-size-fits-all” approach remains a risk. Because insomnia during menopause is caused by a complex mix of hormone fluctuations, aging, psychiatric conditions, and psychosocial stressors, a single treatment like CBT may not address the root cause for every woman.
There is also the ongoing debate regarding the long-term efficacy of non-hormonal drugs versus the established, albeit complex, benefits of HRT. While newer drugs offer relief without the hormonal risks, their long-term impact on bone density and cardiovascular health—areas where estrogen is known to be protective—remains a subject of ongoing clinical observation.
What Happens Next
As these guidelines are implemented across clinical practices, several catalysts will shape the future of menopause care:
Frequently Asked Questions
Is hormone replacement therapy (HRT) safe for menopause?
According to the new ACOG guidelines, the safety of HRT is “well-established” for many women, particularly those who are under the age of 60 or are within 10 years of the onset of menopause. However, safety is highly dependent on an individual’s medical history. Women with a history of certain cancers, blood clots, stroke, or heart disease may be advised to avoid it. Always consult with a healthcare provider to assess your specific risk profile.
What are the non-hormonal options for hot flashes?
There are several non-hormonal options available. Newer FDA-approved medications include fezolinetant (Veozah) and elinzanetant (Lynkuet), which work by targeting the brain’s temperature regulation center. Other options include gabapentin, an anticonvulsant that can manage symptoms for those who cannot use hormones, as well as lifestyle changes like diet and exercise.
How can Cognitive Behavioral Therapy (CBT) help with menopause?
CBT is a psychological treatment that helps patients change the thoughts and behaviors that contribute to sleep issues. It has been shown to be a feasible and effective way to manage menopause-related insomnia and night sweats by improving sleep self-efficacy and reducing the severity of sleep disturbances. Note that some studies suggest its benefits may be most pronounced in the short term, lasting about three months.
Why do I need progestogen if I am taking estrogen?
For women who still have a uterus, ACOG recommends combining estrogen with progestogen. This is because estrogen alone can stimulate the growth of the uterine lining, which increases the risk of endometrial cancer. Progestogen is included in the treatment to help mitigate that specific risk.
As medical understanding of the menopausal transition continues to mature, the shift toward personalized, multi-modal care marks a significant turning point in women’s health
References
Featured image: Photo by Cedric Fauntleroy on Pexels